Skip to main content
OpenTrials
Completed

NCT Number: NCT00186251

High Dose Chemotherapy Followed By PBSC Rescue for HD

To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hodgkin Disease Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

4 week–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

About this study

Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- adequate organ function

  • recurrent HD Exclusion Criteria:- CNS disease
  • no prior malignancy

Treatment and study plan

high dose chemo then auto hematopoietic cell transplant

Procedure

Primary outcomes

  1. Overall survival

  2. FFS

  3. Response rates

Secondary outcomes

  1. Toxicity of high dose chemotherapy

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Important dates

Study start
1998
Study completion
2005
First posted
Sep 16, 2005
Registry last updated
Nov 12, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.